

07-17-2003

Q-61536

Form PTO-1595 (modified)
(Rev. 03/01)
OMB No. 0651-0027

RI



PT

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

102499618

To the Director of the U.S. Patent and Trademark Office, please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Tasuku HONJO, Kei TASHIRO and
Tomoyuki NAKAMURA
Additional name(s) of conveying party(ies) attached? Yes No

7-14-03

2. Name and address of receiving party(ies):
ONO PHARMACEUTICAL CO., LTD.
1-5, Doshomachi 2-chome, Chuo-ku
Osaka-shi, Osaka 541-8526
JAPAN

3. Nature of conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other


Execution Date: November 14, 2000; November 14 2000;
and November 10, 2000

Additional name(s) & address(es) attached? Yes No

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)
09/674,330

B. Patent No.(s)



Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

SUGHRUE MION, PLLC

WASHINGTON OFFICE



23373

PATENT TRADEMARK OFFICE

6. Total number of applications and patents involved:
1

7. Total fee (37 CFR 3.41): \$40.00
 Enclosed.
 Authorized to be charged to Deposit Account No. 19-4880.
The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

8. Deposit Account Number:
19-4880
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

[Signature]

Drew Hissong

Reg. No. 44,765

July 14, 2003

Date

Total number of pages including cover sheet, attachments, and documents: 3

Mail documents to be recorded with required cover sheet information to:

MAIL STOP ASSIGNMENT RECORDATION SERVICES

Director of the U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 23313-1450

07/16/2003 LNUELLER 00000236 09674330

01 FC:0021

40.00 EP

PATENT
REEL: 014265 FRAME: 0751

ASSIGNMENT

Whereas, I/We, Tasuku HONJO and Kei TASHIRO, both of Kyoto, Japan
and Tomoyuki NAKAMURA of California, U.S.A.

8K

hereinafter called assignor(s), have invented certain improvements in

A novel polypeptide, a cDNA encoding the polypeptide and utilization thereof
and executed an application for Letters Patent of the United States of America therefor on

November 14, 2000 ; and


Whereas, ONO Pharmaceutical Co., Ltd. of
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA
541-8526 JAPAN


(assignee), desires to acquire the entire right, title and interest in the application and invention, and
to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named
assignee, its successors and assigns, the entire right, title and interest in the application and the
invention disclosed therein for the United States of America, including the right to claim priority under
35 U.S.C. § 119, and I/we request the Commissioner of Patents to issue any Letters Patent granted
upon the invention set forth in the application to the assignee, its successors and assigns; and I/we
will execute without further consideration all papers deemed necessary by the assignee in connection
with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my attorneys SUGHRUE, MION, ZINN, MACPEAK & SEAS
of 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3202 to insert here in parentheses
(Application number 09/674,330, filed October 30, 2000) the filing
date and application number of said application when known.

Date: November 14, 2000 s/ 

Date: November 14, 2000 s/ 

Date: s/ _____

Date: s/ _____

Date: s/ _____

Date: s/ _____

Date: s/ _____

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. § 261)

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. § 261)

ASSIGNMENT

Whereas, I/We, Tasuku HONJO and Kei TASHIRO, both of Kyoto, Japan
and Tomoyuki NAKAMURA of California, U.S.A.

KK

hereinafter called assignor(s), have invented certain improvements in
A novel polypeptide, a cDNA encoding the polypeptide and utilization thereof
and executed an application for Letters Patent of the United States of America therefor on
November 10, 2000 ; and

Whereas, ONO Pharmaceutical Co., Ltd. of
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA
541-8526 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and
to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named
assignee, its successors and assigns, the entire right, title and interest in the application and the
invention disclosed therein for the United States of America, including the right to claim priority under
35 U.S.C. § 119, and I/we request the Commissioner of Patents to issue any Letters Patent granted
upon the invention set forth in the application to the assignee, its successors and assigns; and I/we
will execute without further consideration all papers deemed necessary by the assignee in connection
with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my attorneys SUGHRUE, MION, ZINN, MACPEAK & SEAS
of 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3202 to insert here in parentheses
(Application number 09/674,330, filed October 30, 2000) the filing
date and application number of said application when known.

Date: s/ _____

Date: s/ _____

Date: November 10, 2000 s/ Tom. Nak

Date: s/ _____

Date: s/ _____

Date: s/ _____

Date: s/ _____

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. § 251)